Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a large increase in short interest in August. As of August 14th, there was short interest totaling 584,609 shares, an increase of 823.5% from the July 30th total of 63,307 shares. Currently, 9.0% of the company’s shares are short sold. Based on an average trading volume of 38,485,659 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Investors Weigh In On Creative Medical Technology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in Creative Medical Technology in the 4th quarter valued at $59,000. Clear Harbor Asset Management LLC bought a new position in shares of Creative Medical Technology during the 2nd quarter worth about $192,000. Finally, Seros Financial LLC bought a new position in shares of Creative Medical Technology during the 2nd quarter worth about $53,000. 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Trading Up 2.5%

NASDAQ CELZ traded up $0.03 on Tuesday, reaching $1.24. The stock had a trading volume of 167,613 shares, compared to its average volume of 3,796,424. Creative Medical Technology has a 1 year low of $0.62 and a 1 year high of $6.25. The business has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.76. The company has a market capitalization of $8.17 million, a price-to-earnings ratio of -0.60 and a beta of 1.95.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, analysts anticipate that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Creative Medical Technology to a “sell” rating in a research report on Saturday. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. Finally, Weiss Ratings raised shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.